Literature DB >> 16338176

Truncation of the C-terminus of human MLH1 blocks intracellular stabilization of PMS2 and disrupts DNA mismatch repair.

Azizah B Mohd1, Brett Palama, Scott E Nelson, Guy Tomer, Megan Nguyen, Xin Huo, Andrew B Buermeyer.   

Abstract

The human DNA mismatch repair (MMR) protein MLH1 has essential roles in the correction of replication errors and the activation of cell cycle checkpoints and cytotoxic responses to DNA damage that contribute to suppression of cancer risk. MLH1 functions as a heterodimer with the PMS2 protein, and steady state levels of PMS2 are very low in MLH1-deficient cells. Unique to MLH1 among MutL-homolog proteins, and conserved in identified eukaryotic MLH1 proteins, is the so-called C-terminal homology domain (CTH). The function of these C-terminal 20-30 amino acids is not known. We investigated the effect of a C-terminal truncation of human MLH1 (MLH1-L749X) on mammalian MMR by testing its activity in MLH1-deficient cells. We found the CTH to be essential for suppression of spontaneous mutation, activation of a cytotoxic response to 6-thioguanine, and maintenance of normal steady state levels of PMS2. Co-expression in doubly mutant Mlh1-/-; Pms2-/- fibroblasts showed that MLH1-L749X was unable to stabilize PMS2. Over-expression of MLH1-L749X did not reduce stabilization of PMS2 mediated by wild-type MLH1, indicating that truncation of the CTH reduces the ability to compete with wild-type MLH1 for interaction with PMS2. Lack of PMS2 stabilization also was observed with a previously reported pathogenic truncation (MLH1-Y750X), but not with two different point mutations in the CTH. Biochemical assays demonstrated that truncation of the CTH reduced the stability of heterodimers, although MLH1-L749X retained significant capacity for interaction with PMS2. Thus, the CTH of human MLH1 is necessary for error correction, checkpoint signaling, and for promoting interaction with, and the stability of, PMS2. Analysis of the CTH role in stabilizing PMS2 was facilitated by a novel intracellular assay for MLH1-PMS2 interaction. This assay should prove useful for identifying additional amino acids in MLH1 and PMS2 necessary for interaction in cells, and for determining the functional consequences of MLH1 mutations identified in human cancers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16338176     DOI: 10.1016/j.dnarep.2005.11.001

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  18 in total

1.  Identification of Lynch syndrome mutations in the MLH1-PMS2 interface that disturb dimerization and mismatch repair.

Authors:  Jan Kosinski; Inga Hinrichsen; Janusz M Bujnicki; Peter Friedhoff; Guido Plotz
Journal:  Hum Mutat       Date:  2010-08       Impact factor: 4.878

2.  An intact Pms2 ATPase domain is not essential for male fertility.

Authors:  Jared M Fischer; Sandra Dudley; Ashleigh J Miller; R Michael Liskay
Journal:  DNA Repair (Amst)       Date:  2015-12-29

3.  The E705K mutation in hPMS2 exerts recessive, not dominant, effects on mismatch repair.

Authors:  Suzanne M Deschênes; Guy Tomer; Megan Nguyen; Naz Erdeniz; Nicole C Juba; Natalia Sepúlveda; Jenna E Pisani; R Michael Liskay
Journal:  Cancer Lett       Date:  2006-10-09       Impact factor: 8.679

4.  A novel and rapid method of determining the effect of unclassified MLH1 genetic variants on differential allelic expression.

Authors:  Sheron Perera; Brian Li; Soultana Tsitsikotas; Lily Ramyar; Aaron Pollett; Kara Semotiuk; Bharati Bapat
Journal:  J Mol Diagn       Date:  2010-09-23       Impact factor: 5.568

5.  Biochemical and structural characterization of two variants of uncertain significance in the PMS2 gene.

Authors:  Brandon M D'Arcy; Jessa Blount; Aishwarya Prakash
Journal:  Hum Mutat       Date:  2019-01-30       Impact factor: 4.878

6.  A founder MLH1 mutation in Lynch syndrome families from Piedmont, Italy, is associated with an increased risk of pancreatic tumours and diverse immunohistochemical patterns.

Authors:  Iolanda Borelli; Guido C Casalis Cavalchini; Serena Del Peschio; Monica Micheletti; Tiziana Venesio; Ivana Sarotto; Anna Allavena; Luisa Delsedime; Marco A Barberis; Giorgia Mandrile; Paola Berchialla; Paola Ogliara; Cecilia Bracco; Barbara Pasini
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

7.  The C-terminal domain of the MutL homolog from Neisseria gonorrhoeae forms an inverted homodimer.

Authors:  Sivakumar Namadurai; Deepti Jain; Dhananjay S Kulkarni; Chaitanya R Tabib; Peter Friedhoff; Desirazu N Rao; Deepak T Nair
Journal:  PLoS One       Date:  2010-10-28       Impact factor: 3.240

8.  The FANCJ/MutLalpha interaction is required for correction of the cross-link response in FA-J cells.

Authors:  Min Peng; Rachel Litman; Jenny Xie; Sudha Sharma; Robert M Brosh; Sharon B Cantor
Journal:  EMBO J       Date:  2007-06-21       Impact factor: 11.598

9.  Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for Lynch syndrome.

Authors:  Israel Zighelboim; Matthew A Powell; Sheri A Babb; Alison J Whelan; Amy P Schmidt; Mark Clendenning; Leigha Senter; Stephen N Thibodeau; Albert de la Chapelle; Paul J Goodfellow
Journal:  Fam Cancer       Date:  2009-08-12       Impact factor: 2.375

10.  MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition.

Authors:  X Ding; A B Mohd; Z Huang; T Baba; M Q Bernardini; H K Lyerly; A Berchuck; S K Murphy; A B Buermeyer; G R Devi
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.